Medtronic’s drug-eluting stent system gets European approval
‘The Endeavour drug-eluting coronary stent system, which incorporates components developed by Abbott, Medtronic, Biocompatibles, and ScinoPharm, has been approved for marketing in Europe for the use during heart operations for coronary artery disease.
Stents are used to keep arteries open during heart surgery. The Endeavour stent is known as a drug-eluting stent, which is coated with a drug that helps to prevent the re-clogging of arteries after the procedure.
The Endeavor stent combines Abbott’s patented drug Zotarolimus, Medtronic’s Driver Coronary Stent platform, and Biocompatibles PC Polymer into a drug-eluting stent system. ‘
Read more at Medtronic’s drug-eluting stent system gets European approva
Recent Entries
- Sigma Pharmaceuticals year profit rises 27 pct
- South African citizens cheap drug guinea pigs
- Two drugs test victims face a year in coma
- Can drug companies improve their reputation?
- Pfizer Sees 40 Percent Rise in 2006 Net on Cost Cuts
- Pfizer’s Forecast Disappoints
- Pharmaceutical RFID Adoption Stalls
- Inhalable Drug Might Bring Sigh Of Relief To Diabetes Patients
- GlaxoSmithKline unveils best results since merger
- Pfizer Sues Teva, Sandoz Over Zithromax